Resources for Researchers

NIAID offers many resources to support your research, including reagents, model organisms, and tissue samples, to name just a few. Use the filters under Filter Search Results to narrow your search, or simply enter specific search terms in the search field.

Showing results filtered by:
Clear All
Translational

47 Results

Developing, characterizing, and refining animal models are key to advancing medical countermeasures for high-consequence pathogens.

The ARLG biorepositories were created to aid in the development and evaluation of novel diagnostic tests and laboratory techniques, study mechanisms of resistance, generate preliminary data for study concepts, and support/mentor early-stage investigators pursuing research in the field of antibacterial resistance.

Artificial intelligence (AI), in its many forms, is applied to infectious disease research at the IRF-Frederick. Primarily focused on medical imaging of preclinical models, state of the art methods are developed, applied to ongoing research and translated to human studies of disease.

The BEI Resources Repository is a central repository that supplies organisms and reagents to the broad community of microbiology and infectious diseases researchers. Materials are available through an online catalog.

The National Emerging Infectious Diseases Laboratories (NEIDL) is one of two National Biocontainment Laboratories constructed under a grant from the National Institute of Allergy and Infectious Diseases.

The Colorado State University Regional Biocontainment Laboratory is one of the NIAID-supported Regional Biocontainment Laboratories. The Center provides a safe, secure, state of art facility for university investigators, government scientists and industry representatives to collaboratively research bacteria and viruses that cause human and animal diseases

An overview of the NIAID-supported Duke Human Vaccine Institute (DHVI) Regional Biocontainment Lab (RBL) at The Duke University School of Medicine.

George Mason University's Biomedical Research Laboratory (BRL) is one of the NIAID supported Regional Biocontainment Laboratories. It operates as a central core facility in the Institute for Biohealth Innovation to advance research and develop novel diagnostics, therapeutics, and vaccines against viral and bacterial infectious agents by a diverse population of investigators.

The Rutgers University Regional Biocontainment Laboratory is one of the NIAID-supported Biocontainment Laboratories. The RBL is a highly secure facility designed to provide an ultra-safe work environment for scientists and support staff, as well as the public at large.

The Tufts New England Regional Biosafety Laboratory (RBL) is one of the NIAID-supported Regional Biocontainment Laboratories. The RBL is a 41,000 square foot resource available to researchers in industry, academia, government and not-for-profit, dedicated to the study of existing and emerging infectious diseases, toxin-mediated diseases and medical countermeasures important to biodefense.

The Tulane University Regional Biosafety Laboratory (RBL) at The Tulane National Primate Research Center is one of the NIAID-supported Biocontainment Laboratories.

The regional biocontainment laboratory at University of Alabama at Birmingham (UAB), called Southeastern Biosafety Laboratory Alabama Birmingham (SEBLAB), is one of the NIAID-supported Biocontainment Laboratories. The Lab houses state-of-the art biosafety level 2 and level 3 laboratories as well as animal biosafety level 3 laboratories.

The University of Chicago Howard T. Ricketts Laboratory (HTRL) is one of the NIAID-supported Biocontainment Laboratories.  The HTRL is a state of the art BSL-3 facility constructed to support research on bacterial and viral pathogens.

The Regional Biocontainment Lab (RBL) at the Center for Predictive Medicine is one of the NIAID-supported Biocontainment Laboratories. The Lab provides a valuable national resource and asset to the University of Louisville, our region, and the greater scientific and public health communities. The Lab has been built to the most stringent federal standards

The University of Pittsburgh Regional Biocontainment Laboratory is one of the NIAID-supported Biocontainment Laboratories.

The University of Tennessee Regional Biocontainment Laboratory (RBL) is one of the NIAID-supported Biocontainment Laboratories. The RBL provides a secure lab for conducting research on Category A and B infectious pathogens using state-of-the-art molecular pathogenesis and immunologic approaches.

As one of two National Biocontainment Laboratories constructed under grants awarded by the National Institute of Allergy and Infectious Diseases/National Institutes of Health (NIAID/NIH), the Galveston National Laboratory (GNL) enables progress in our understanding of the fundamental mechanisms underlying the spread of infectious diseases and the pathogenesis of the diseases they cause.

NIAID CEIRS provides the BEI Resources Repository with high-priority reagents from the CEIRS community. Reagents include plasmids, antibodies, proteins, and virus isolates. Reagents not available through BEI can be requested on this page. Non-BEI reagents may be available from CEIRS researchers upon request.

    The CIBMTR database contains data on outcomes of hematopoietic (blood and bone marrow) cell transplant (HCT) procedures. The CIBMTR collaborates with government agencies, professional groups, international partners, and patient organizations via 15 active scientific/research working committees.

    The Chemistry Center for Combating Antibiotic-Resistant Bacteria (CC4CARB) is a NIAID-led partnership with RTI International, which oversees the design, synthesis, and management of external investigator-submitted libraries of chemical compounds specifically targeting Gram-negative bacteria.

    The Clinical Study Support Team (CSST) is a deployable team with the primary objective of developing and fostering overseas relationships through the support of research studies and clinical trials involving pathogens of high consequence.

    This contract provides gap-filling support services for HIV prevention drug developers including academic (investigators), for-profit and not-for-profit small and large companies, and other product innovators (henceforth identified as Sponsors) for the development of HIV non-vaccine biomedical prevention (nBP) strategies and products.

    Repository of specimens collected as part of the DAIDS VAX004 Clinical Trial.

    The STAT3base contains a listing of STAT3 mutations in human HIES identified in the Laboratory of Clinical Immunology and Microbiology as well as those published in the literature.